| scholarly article | Q13442814 |
| P50 | author | Luis Querol | Q87845994 |
| Jeffrey A Allen | Q88155314 | ||
| Krista Kuitwaard | Q98901052 | ||
| P2093 | author name string | Melvin Berger | |
| Robert D Hadden | |||
| P2860 | cites work | Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study | Q40011079 |
| CIDP diagnostic pitfalls and perception of treatment benefit | Q40730855 | ||
| Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin | Q41766911 | ||
| Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS. | Q42155763 | ||
| Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy | Q43083591 | ||
| Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. | Q43742502 | ||
| Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor | Q44193574 | ||
| Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders | Q45640650 | ||
| Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. | Q45973638 | ||
| Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. | Q46020925 | ||
| Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47419841 | ||
| Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy | Q47584292 | ||
| The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. | Q47673920 | ||
| Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy | Q48229967 | ||
| Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis | Q48510258 | ||
| A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. | Q50736664 | ||
| Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement. | Q50882404 | ||
| Autoantibodies to neurofascin-186 and gliomedin in multifocal motor neuropathy. | Q51693018 | ||
| An open label clinical trial of complement inhibition in multifocal motor neuropathy. | Q53239243 | ||
| A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients. | Q53647790 | ||
| A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside | Q69836574 | ||
| High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events | Q72776648 | ||
| Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases | Q77814999 | ||
| Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy | Q79373553 | ||
| Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial | Q80454073 | ||
| Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies | Q83481138 | ||
| Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report | Q84468963 | ||
| Response to treatment in patients with Lewis-Sumner syndrome | Q84557142 | ||
| Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome | Q84950858 | ||
| Immunoglobulin (Ig) in multifocal motor neuropathy (MMN): update on evidence for Ig treatment in MMN | Q86421405 | ||
| Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy | Q86503267 | ||
| Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies | Q26864907 | ||
| Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg | Q30574385 | ||
| FcγRIIB and autoimmunity | Q30981881 | ||
| Effect of high-dose intravenous immunoglobulin therapy on blood rheology | Q33351934 | ||
| Intravenous immunoglobulin therapy: how does IgG modulate the immune system? | Q33405903 | ||
| MMN: from immunological cross-talk to conduction block | Q33729418 | ||
| IgG subclasses and allotypes: from structure to effector functions | Q34368678 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Pe | Q34619228 | ||
| Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern | Q35141051 | ||
| Subcutaneous immunoglobulin replacement in primary immunodeficiencies | Q35811020 | ||
| Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia | Q36186804 | ||
| Neurofascin as a target for autoantibodies in peripheral neuropathies | Q36524437 | ||
| Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency | Q36688462 | ||
| Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy | Q36691991 | ||
| NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences. | Q37153919 | ||
| Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes | Q37304914 | ||
| Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. | Q37635865 | ||
| CIDP - the relevance of recent advances in Schwann cell/axonal neurobiology | Q37866845 | ||
| 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands | Q38120132 | ||
| Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach | Q38270717 | ||
| The expanding field of IgG4-mediated neurological autoimmune disorders | Q38511298 | ||
| Paranodal and other autoantibodies in chronic inflammatory neuropathies | Q38564560 | ||
| Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. | Q38748481 | ||
| IVIG in autoimmune disease - Potential next generation biologics. | Q38790932 | ||
| An overview of the diagnosis and management of immunoglobulin G4-related disease | Q38871355 | ||
| Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies. | Q38873864 | ||
| Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness | Q39101583 | ||
| Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? | Q39424607 | ||
| Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. | Q39434973 | ||
| Metabolism of immunoglobulins | Q39878114 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 78-87 | |
| P577 | publication date | 2018-04-19 | |
| P1433 | published in | Journal of the Peripheral Nervous System | Q15764031 |
| P1476 | title | Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies | |
| P478 | volume | 23 |
| Q64239878 | Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy | cites work | P2860 |
Search more.